The oversubscription of Arvinas's private placement suggests a high level of investor confidence, which typically leads to a positive short-term impact on the stock price. The substantial amount raised can be used to fund ongoing research and development, which is critical for a biotechnology company like Arvinas. This financial boost is likely to be viewed favorably by the market, hence the positive score.